Stocks
Orexigen Therapeutics, Inc.OREX
NASDAQHealthcareBiotechnology$0.22-9.87%
Once focused on developing therapies for obesity and related metabolic disorders, the company’s primary asset was Contrave, a prescription weight‑management drug co-developed with Takeda Pharmaceutical. Financial strain and disputes over commercialization led to a Chapter 11 bankruptcy filing in 201...
Market Cap: $052W Range: $0.17 – $3.81
Congressional Interest in Orexigen Therapeutics, Inc. (OREX)
3 members of Congress have disclosed 3 trades in Orexigen Therapeutics, Inc. (OREX), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 2 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
3
Unique Politicians
3
Buys
1
Sells
2
Who in Congress Is Trading OREX?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2018-01-10 | KENNY MARCHANT | buy | $1K – $15K |
| 2018-01-05 | ALAN S. LOWENTHAL | sell | $11 – $99 |